Dravet Syndrome (DS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Dravet Syndrome (DS) Emerging Therapy and TPP Insights

Thelansis's "Dravet Syndrome (DS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Dravet Syndrome (DS) Overview

Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare and refractory genetic epilepsy that typically begins in the first year of life. The disorder is primarily characterized by frequent, prolonged seizures often triggered by hyperthermia, such as fevers or warm baths, and eventually progresses to include multiple seizure types including myoclonic and atypical absence seizures. Approximately 80 to 85 percent of cases result from a mutation or deletion in the SCN1A gene, which encodes the Nav1.1 voltage-gated sodium channel essential for the function of inhibitory neurons. While most of these mutations occur spontaneously, a small percentage are part of the GEFS+ familial spectrum, and other cases may involve mutations in the PCDH19 gene or somatic mosaicism. In addition to seizures, the syndrome is associated with significant developmental delays, ataxia, hypotonia, and sleep disturbances. Management is particularly complex because common sodium-channel-blocking medications can paradoxically increase seizure frequency, requiring the use of specific treatments such as stiripentol, fenfluramine, or cannabidiol to achieve better seizure control.

Key Highlights

• In Germany, mutation-positive Dravet Syndrome cases are projected to increase from 1,749 in 2025 to 1,781 by 2035.
• Dravet Syndrome is a severe developmental and epileptic encephalopathy typically caused by SCN1A mutations.
• Patients experience treatment-resistant seizures and substantial neurodevelopmental impairment.
• Increasing use of targeted therapies is improving seizure control and patient outcomes.

Market Overview

• The France Dravet Syndrome market is projected to grow from $99.75M in 2025 to $262.5M by 2035.
• Market growth is driven by:
• Adoption of novel anti-seizure therapies
• Increasing use of precision medicine approaches
• Future expansion will depend on disease-modifying and gene-based therapies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Ionis Pharmaceuticals, Inc.
• Stoke Therapeutics, Inc.
• Encoded Therapeutics
• UCB BIOSCIENCES, Inc.
• Epygenix
• Longboard Pharmaceuticals
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• Takeda
• Zogenix, Inc.
• Bright Minds Biosciences Pty Ltd.
• Jazz Pharmaceuticals
• Biocodex